Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-15 stimulated NK cells
- Development stage
- Unknown
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
IL-15 stimulated NK cells are natural killer (NK) cells that have been activated or expanded ex vivo using interleukin-15 (IL-15), a cytokine critical for the development, survival, and activation of NK and CD8+ T-cells. Stimulation with IL-15 enhances the cytotoxic activity of these NK cells by upregulating activating receptors such as NKG2D and TIM-3, increasing their ability to target and kill tumor or infected cells[1][5]. These enhanced effector functions make them promising candidates for adoptive cell therapy in cancer immunotherapy settings. Clinical trials have evaluated the safety and efficacy of infusing ex vivo IL-15-stimulated NK cells in patients with high-risk leukemias following hematopoietic stem cell transplantation[10]. The approach aims to boost graft-versus-leukemia effects while minimizing relapse risk.
- Other names
- ex vivo IL-15 activated NK cellsIL-15 primed NK cellsIL15 primed NK cellsIL 15 primed NK cells
02
Targets
IL2RB (IL-2 receptor beta chain)NKG2D (Natural killer group 2 member D receptor)HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)
Beyond the preview
Go deeper on IL-15 stimulated NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-15 stimulated NK cells.